CDTX Cidara Therapeutics

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.

Presentation Information:

Date: Thursday, June 18, 2020
Time: 3:40 PM ET
Webcast: A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at

About Cidara Therapeutics

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:

Brian Ritchie

LifeSci Advisors

(212) 915-2578

MEDIA CONTACT:

Karen O’Shea, Ph.D.

LifeSci Communications

(929) 469-3860

 

EN
11/06/2020

Underlying

CDTXCidara Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

Free Trial
CDTX Cidara Therapeu...

Cidara Therapeutics Inc: 1 director

A director at Cidara Therapeutics Inc maiden bought 3,320 shares at 22.258USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

CDTX CIDARA THERAPEUTICS
06/05/25 June 5, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Pote...

Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, The event will feature key opinion leaders (KOLs) Fred Hayde...

May 15, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics to Participate in Two Upcoming Investor Conference...

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be ac...

May 13, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Provides Corporate Update and Reports First Quarte...

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief ...

Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. “These promotions come at a pivotal time as we ...

May 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch